Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03065725 | Early Versus Late FDG-PET/CT in Bladder Cancer | completed | — | 179 | Jørgen Bjerggaard JensenOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT03385798 | Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy(EGIAES) | completed | N/A | 90 | Jørgen Bjerggaard JensenOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT04314245 | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma | completed | — | 1,170 | AnchorDx Medical Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT03801954 | Implementation of Nutrition Education Videos for Patients Undergoing Radical Cystectomy | completed | — | 15 | University of Kansas Medical CenterOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02043665 | CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)(STORM) | completed | Phase 1 | 85 | ViralyticsINDUSTRY | 3 | May 6, 2023 | clinicaltrials |
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 2 | Apr 13, 2023 | clinicaltrials |
| NCT03472274 | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)(DUTRENEO) | completed | Phase 2 | 101 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04487457 | Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy(CINECI) | completed | — | 31 | University Hospital, ToursOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05799456 | Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma | completed | — | 106 | Jens NielsenOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04209192 | Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB) | completed | Phase 2 | 75 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05324033 | Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer | completed | — | 30 | Helwan UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT03718754 | En-bloc vs Conventional Resection of Primary Bladder Tumor(eBLOC) | completed | Phase 3 | 384 | David D'AndreaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03854721 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | completed | Phase 1 | 6 | Vaxiion TherapeuticsINDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT02217891 | IFACT: Incidental Findings in Advanced Cancer Therapy(IFACT) | completed | — | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02281383 | Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03058757 | The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation | completed | Phase 2 | 71 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03212651 | Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab(PANDORE) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03434132 | Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion. | completed | N/A | 116 | Regina Elena Cancer InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03307200 | Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy | completed | — | 90 | University Hospital, GhentOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04598724 | Addressing Barriers to Palliative Care Use in Bladder Cancer | completed | — | 54 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT00805129 | Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT03066310 | Urine-DNA Biomarkers in Detecting Bladder Cancer | completed | — | 125 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03325231 | Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy | completed | — | 140 | Swansea UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03584659 | Patient-reported Outcomes in Bladder Cancer(iBLAD) | completed | N/A | 230 | Rigshospitalet, DenmarkOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02437370 | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | completed | Phase 1 | 32 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02811952 | Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients | completed | — | 100 | Carmel Medical CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | completed | Phase 1 | 18 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT01869413 | Tranexamic Acid During Cystectomy Trial (TACT)(TACT) | completed | Phase 2 / Phase 3 | 354 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | completed | Phase 2 | 108 | Matthew GalskyOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03505112 | The Effect of Goal-directed Hemodynamic Therapy in Radical Cystectomy | completed | N/A | 82 | Seoul National University HospitalOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer(OPTIMA II) | completed | Phase 2 | 63 | UroGen Pharma Ltd.INDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03662204 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | completed | — | 5,133 | Exact Sciences CorporationINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05376631 | Effect of Fresh Gas Flow on Emergence Time | completed | N/A | 54 | Asan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05184725 | CARINAE for Stress Relief in Perioperative Care(CARINAE) | completed | N/A | 50 | Adhera Health, Inc.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | completed | Phase 2 | 200 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02993211 | Transurethral En Bloc Versus Standard Resection of Bladder Tumour | completed | N/A | 350 | Chinese University of Hong KongOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT00777491 | Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery | completed | Phase 2 | 70 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 15, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05082818 | Outcome of Treating Bladder Cancer in Sohag University Hospital | completed | — | 168 | Sohag UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05362539 | Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria | completed | N/A | 246 | Mansoura UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03628716 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | completed | Phase 2 | 43 | Bavarian NordicINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05290623 | High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer | completed | — | 45 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05273593 | Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment(CLETUR) | completed | N/A | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04570176 | Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System | completed | N/A | 1 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2023source: clinicaltrials